Analytical Data
-
Gene name
CBFB
- Application
-
Alternative Names
CBF-B; PEBP2B; Polyomavirus enhancer-binding protein 2 beta subunit; SL3-3 enhancer factor 1 subunit beta; SL3/AKV core-binding factor beta subunit
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q08024
-
Expression Region
Met1~Arg187
-
Molecular Weight
26kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CBFB (core-binding factor beta) is a critical component of the core-binding factor (CBF) complex, which plays an essential role in hematopoiesis and development. The CBFB gene encodes a transcription factor that partners with RUNX proteins to regulate the expression of genes involved in cell differentiation, proliferation, and survival. Dysregulation of CBFB has been implicated in various hematological malignancies, particularly acute myeloid leukemia (AML). CBFB rearrangements, such as CBFB-MYH11 fusion, have been shown to disrupt normal hematopoietic development and contribute to leukemogenesis, making it a significant target for therapeutic intervention. Researchers have focused on characterizing the structure and function of CBFB as well as developing recombinant protein forms for functional studies. These studies aim to elucidate the mechanisms by which CBFB influences gene expression and cellular behavior, providing insights into its role in cancer biology. Understanding the biology of CBFB and its interactions can pave the way for targeted therapies that may improve treatment outcomes for patients with malignancies associated with CBFB abnormalities. The development of recombinantly expressed CBFB proteins has also enabled high-throughput screening of small molecules that may inhibit its oncogenic functions, further contributing to the potential for novel therapeutic strategies.
